New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases

Ferrer, Jennifer R.; Chokechanachaisakul, Attasit; Wertheim, Jason A.

doi:10.1007/s40472-015-0059-4

Cited by 12 publications

(9 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatocytes are typically harvested from livers not suitable for transplantation, with a consequent variability in their quantity and quality [53]. Hepatocytes also rapidly lose their proliferative ability when cultured in vitro, and they are sensitive to freeze-thaw damage so their viability and engraftment are affected by culture and cryopreservation methods [54]. Innovative technologies that can expand, maintain, mature, and create hepatocytes in vitro, or alternative sources of cells are consequently required for future cell-based therapies for liver diseases.…”

Section: Alternatives To Liver Transplantationmentioning

confidence: 99%

New Perspectives in Liver Transplantation: From Regeneration to Bioengineering

2019

View full text Add to dashboard Cite

Advanced liver diseases have very high morbidity and mortality due to associated complications, and liver transplantation represents the only current therapeutic option. However, due to worldwide donor shortages, new alternative approaches are mandatory for such patients. Regenerative medicine could be the more appropriate answer to this need. Advances in knowledge of physiology of liver regeneration, stem cells, and 3D scaffolds for tissue engineering have accelerated the race towards efficient therapies for liver failure. In this review, we propose an update on liver regeneration, cell-based regenerative medicine and bioengineering alternatives to liver transplantation.

show abstract

Section: Alternatives To Liver Transplantationmentioning

confidence: 99%

New Perspectives in Liver Transplantation: From Regeneration to Bioengineering

2019

View full text Add to dashboard Cite

show abstract

“…Hepatocytes are typically harvested from livers not suitable for transplantation, with the variability in quantity and quality that this entails (12). Furthermore, storage of hepatocytes is not without its complications, as these cells are sensitive to freeze-thaw damage so that viability and engraftment are affected by cryopreservation (13). Consequently, alternative sources of cells are being actively sought after.…”

Section: Primary Hepatocytesmentioning

confidence: 99%

Cell therapy in chronic liver disease

Nicolas

Wang

Nyberg

2016

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of review To date, the only curative treatment for end-stage liver disease is liver transplantation, which is limited by the shortage of available organs. Cell therapy, in the form of cell transplantation or cell-based extracorporeal support devices, may in the future offer an alternative to transplantation, or at least provide liver function support as a bridging therapy until surgery may be performed. The purpose of this review is to highlight the most recent advances made in the field of cell therapy and regenerative medicine for the treatment of chronic liver disease (CLD). Recent findings After hepatocyte transplantation, long-term engraftment in the liver and spleen may be achieved, which can be stimulated through preconditioning, multiple infusions, and inflammatory response blockade. Mesenchymal stem cells are promising candidates for cell transplantation, as they have been shown to reduce liver fibrosis and support endogenous regeneration. Adipose tissue-derived stem cells are also being tested in this setting, due to their ready availability. Bioartificial liver (BAL) devices are being built that allow for effective preservation of hepatocytes, and one such device has recently demonstrated survival benefit in a porcine model of liver failure. Summary Cell transplantation of primary hepatocytes or stem cell-derived hepatocyte-like cells (HLCs) for the treatment of CLD holds promise. BAL systems may in the future be able to bridge acute-on-chronic liver failure patients to liver transplantation.

show abstract

“…The idea of using hepatocytes to treat liver failure depends on a simple hypothesis that liver function can be improved by supplementing exogenous hepatocytes. Although liver failure can be treated via hepatocyte transplantation, it also faces multiple problems comprising the shortage of high-quality hepatocytes sources, rejection of allogeneic transplants, difficulty to expand, and losing hepatic characteristics in vitro [ 7 , 8 ]. Previous studies have proven that rodent and human MSCs can differentiate into HLCs in vitro and in vivo , which is one of the mechanisms of MSCs in the treatment of liver failure.…”

Section: Introductionmentioning

confidence: 99%

Progress in mesenchymal stem cell–based therapy for acute liver failure

Wang

Chen

et al. 2018

Stem Cell Res Ther

View full text Add to dashboard Cite

Acute liver failure is a life-threatening clinical syndrome characterized by rapid development of hepatocellular necrosis leading to high mortality and resource costs. Numerous treatment strategies for acute liver failure simply prevent complications and decelerate disease progression. The only curative treatment for acute liver failure is liver transplantation, but there are many restrictions on the application of liver transplantation. In recent years, a growing number of studies have shown that stem cells can effectively treat acute liver failure. Several types of stem cells have been used to study liver diseases; mesenchymal stem cells are most commonly used because they are easy to obtain and present no ethical problems. The aims of this article are to review the current knowledge regarding therapeutic mechanisms of mesenchymal stem cells in acute liver failure, to discuss recent advancements in preclinical and clinical studies in the treatment of mesenchymal stem cells, and to summarize the methodological improvement of mesenchymal stem cell transplantation in treating liver failure.

show abstract

New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases

Cited by 12 publications

References 93 publications

New Perspectives in Liver Transplantation: From Regeneration to Bioengineering

New Perspectives in Liver Transplantation: From Regeneration to Bioengineering

Cell therapy in chronic liver disease

Progress in mesenchymal stem cell–based therapy for acute liver failure

Contact Info

Product

Resources

About